Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 1,756 shares of the business's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the completion of the sale, the chief financial officer now directly owns 61,065 shares in the company, valued at $2,808,990. This trade represents a 2.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Asif Ali also recently made the following trade(s):
- On Wednesday, March 12th, Asif Ali sold 24,903 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19.
Protagonist Therapeutics Stock Performance
Shares of NASDAQ:PTGX opened at $46.16 on Thursday. The business has a fifty day moving average of $45.32 and a 200-day moving average of $42.84. Protagonist Therapeutics, Inc. has a twelve month low of $24.22 and a twelve month high of $60.60. The firm has a market cap of $2.83 billion, a PE ratio of 17.35 and a beta of 2.30.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $170.64 million during the quarter, compared to analysts' expectations of $56.65 million. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have commented on PTGX. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. JPMorgan Chase & Co. raised their target price on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. BMO Capital Markets upped their price target on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Truist Financial increased their price objective on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a research note on Tuesday, March 11th. Finally, The Goldman Sachs Group reduced their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, February 24th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.44.
Read Our Latest Research Report on PTGX
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC bought a new position in Protagonist Therapeutics in the 4th quarter valued at $38,000. GAMMA Investing LLC lifted its stake in shares of Protagonist Therapeutics by 153.3% during the first quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock valued at $58,000 after acquiring an additional 728 shares during the period. GF Fund Management CO. LTD. bought a new position in Protagonist Therapeutics in the fourth quarter valued at about $48,000. Covestor Ltd increased its position in Protagonist Therapeutics by 5,200.0% in the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after purchasing an additional 1,612 shares during the period. Finally, KBC Group NV increased its position in Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares during the period. Institutional investors own 98.63% of the company's stock.
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.